Drug firm Lupin on Friday said it has received approval from the Canadian health regulator for its Propranolol Hydrochloride extended-release capsules used for treatment of hypertension and decrease frequency of angina.
The company has received approval for its Propranolol Hydrochloride extended-release (ER) capsules in the strengths of 60 mg, 80 mg, 120 mg and 160 mg from Health Canada, Lupin said in a statement.
Lupin is the first generic company to receive an approval for generic Inderal-LA capsules for the Canadian market and the product will be manufactured at the company's Pithampur unit-2 facility, it added.
The company's product is the generic version of Pfizer Canada ULC's Inderal-LA capsules in the same strengths, Lupin said.
As per IQVIA MAT December 2018 data, Propranolol Hydrochloride ER capsules had an annual sales of approximately CAD 8.6 million in the Canadian market, it added.
The capsules are indicated in the treatment of hypertension and for the prophylaxis of angina pectoris, Lupin said.
Shares of Lupin settled at Rs 763.80 per scrip on the BSE, up 0.61 per cent from its previous close.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.